» Articles » PMID: 1692346

Translation by the Adenovirus Tripartite Leader: Elements Which Determine Independence from Cap-binding Protein Complex

Overview
Journal J Virol
Date 1990 Jun 1
PMID 1692346
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

The adenovirus tripartite leader is a 200-nucleotide-long 5' noncoding region which facilitates translation of viral mRNAs at late times after infection. The tripartite leader also confers the ability to initiate translation independent of the requirement for cap-binding protein complex or eIF-4F without any requirement for adenovirus gene products. To elucidate the manner by which the tripartite leader functions, the primary determinants of leader activity were investigated in vivo by testing a series of mutations expressed from transfected plasmids. The results of these experiments indicate that the tripartite leader does not promote internal ribosome binding, at least in a manner recently described for picornavirus mRNAs. In addition, despite an unusual arrangement of sequences complementary to the 3' end of 18S rRNA in the tripartite leader, we could find no evidence for involvement in its translation activity. Instead, our results are consistent with a model in which much of the first leader is maintained in an unstructured conformation which determines the ability of the tripartite leader to facilitate translation and bypass a normal requirement for eIF-4F activity. Several possible translation models are discussed, as well as the implications for translation of late viral mRNAs.

Citing Articles

Global Transcriptome Analyses of Cellular and Viral mRNAs during HAdV-C5 Infection Highlight New Aspects of Viral mRNA Biogenesis and Cytoplasmic Viral mRNA Accumulations.

Aleman M, Bertzbach L, Speiseder T, Ip W, Gonzalez R, Dobner T Viruses. 2022; 14(11).

PMID: 36366526 PMC: 9692883. DOI: 10.3390/v14112428.


E1B-55K Is a Phosphorylation-Dependent Transcriptional and Posttranscriptional Regulator of Viral Gene Expression in Human Adenovirus C5 Infection.

Hidalgo P, Garces Y, Mundo E, Lopez R, Bertzbach L, Dobner T J Virol. 2022; 96(5):e0206221.

PMID: 35019711 PMC: 8906433. DOI: 10.1128/jvi.02062-21.


Effect of adenovirus infection on transgene expression under the adenoviral MLP/TPL and the CMVie promoter/enhancer in CHO cells.

El-Mogy M, Abdalla M, Misic V, Haj-Ahmad Y J Genet Eng Biotechnol. 2019; 15(1):211-217.

PMID: 30647657 PMC: 6296590. DOI: 10.1016/j.jgeb.2017.04.003.


The tripartite leader sequence is required for ectopic expression of HAdV-B and HAdV-E E3 CR1 genes.

Bair C, Narayan P, Kajon A Virology. 2017; 505:139-147.

PMID: 28259047 PMC: 7444620. DOI: 10.1016/j.virol.2017.02.021.


Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains.

Hidajat R, Kuate S, Venzon D, Kalyanaraman V, Kalisz I, Treece J Vaccine. 2010; 28(23):3963-71.

PMID: 20382241 PMC: 2875308. DOI: 10.1016/j.vaccine.2010.03.046.


References
1.
Berkner K, Sharp P . Effect of the tripartite leader on synthesis of a non-viral protein in an adenovirus 5 recombinant. Nucleic Acids Res. 1985; 13(3):841-57. PMC: 341038. DOI: 10.1093/nar/13.3.841. View

2.
SANGER F, Nicklen S, Coulson A . DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977; 74(12):5463-7. PMC: 431765. DOI: 10.1073/pnas.74.12.5463. View

3.
De Benedetti A, Baglioni C . Inhibition of mRNA binding to ribosomes by localized activation of dsRNA-dependent protein kinase. Nature. 1984; 311(5981):79-81. DOI: 10.1038/311079a0. View

4.
Lopata M, Cleveland D . High level transient expression of a chloramphenicol acetyl transferase gene by DEAE-dextran mediated DNA transfection coupled with a dimethyl sulfoxide or glycerol shock treatment. Nucleic Acids Res. 1984; 12(14):5707-17. PMC: 320025. DOI: 10.1093/nar/12.14.5707. View

5.
Gorman C, Moffat L, Howard B . Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol. 1982; 2(9):1044-51. PMC: 369897. DOI: 10.1128/mcb.2.9.1044-1051.1982. View